DRKS00002954CompletedNot Applicable
The effect of radiation therapy of the prostate on parameters, which can be acquired by magnetic resonance tomography: relaxation times, apparent diffusion coefficient and perfusion. - N/A
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- niversitätsklinikum Freiburg
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- Male
Inclusion Criteria
- •Male patients older than 18 years, with histologically confirmed prostate cancer.
- •- Where the biopsy at the time of the first MR examination at least 6 weeks is back
- •- The radiation therapy can be obtained as primary therapy (5 x 2 Gy / week up to a total dose of 72-76 Gy)
- •- Have no restriction on the kidney function.
- •- No contraindications for the whole-body MRI
- •- Consent to participate in the study after detailed explanation of previous and written consent
Exclusion Criteria
- •- TURP prior to study inclusion
- •- Pre-irradiation in the pelvic area
- •- Start an anti-hormonal therapy prior to study entry
- •- Contraindications to MR studies (pacemakers, metallic clips after magnetizable brain or heart surgery, cochlear implants, metallic foreign body in the eye, insulin pumps, etc.).
- •- Ferromagnetic intracorporeal debris
- •- SM / AICD implantation
- •- Lack of written informed consent
- •- Combined radiation therapy (HDR afterloading percutaneous)
- •- Severe allergic diathesis
- •- Known allergy to contrast agent gadolinium-chelates
- •- Renal (filtration rate <40 ml / min)
- •- prior kidney and liver transplant
Investigators
Similar Trials
Recruiting
Not Applicable
Radiation sensitivity in prostate cancer patientsCancer - ProstateProstate CancerACTRN12605000538640ROYAL ADELAIDE HOSPITA100
Completed
Not Applicable
Radiotherapy for prostate cancer: Influence of fiducial marker on diffusion weighted MR imageProstate cancerJPRN-UMIN000036326Asahi University20
Completed
Phase 2
A trial of prostate radiotherapy in conjunction with carbogen and nicotinamideMalignant neoplasm of prostateCancerProstate cancerISRCTN08912168East and North Hertfordshire Hospitals NHS Trust (UK)50
Active, not recruiting
Phase 1
Prostate Radiotherapy with Oxygen EnhancementMedDRA version: 14.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate CancerEUCTR2010-021886-63-GBEast and North Hertfordshire NHS Trust50
Completed
Not Applicable
Research on radiation therapy for prostate ductal carcinoma and small cell carcinomaprostate ductal carcinoma and small cell carcinomaJPRN-UMIN000037617Japanese Radiation Oncology Study Group100